Press releases – Alligator Bioscience

2024-12-03 | Alligator Bioscience resolves on conversion of series C shares into ordinary shares for delivery to participants in incentive program Downloads

2024-12-02 | Exercise price determined for the exercise of warrants series TO 9 in Alligator Bioscience AB Downloads

2024-12-02 | Notice of extraordinary general meeting in Alligator Bioscience AB Downloads

2024-12-02 | Alligator sharpens focus on mitazalimab and announces cost reduction program to maximize long-term value creation Downloads

2024-12-02 | Alligator Bioscience carries out a rights issue of units of approximately SEK 280 million and raises bridge loans Downloads

2024-11-19 | Alligator announces sale of future financial commitments for two bispecific antibodies to Orion Corporation Downloads

2024-11-11 | First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial Downloads

2024-11-06 | Alligator Bioscience Presents an Update with Clinical and Biomarker Results with Mitazalimab in Phase 2 Pancreatic Cancer at SITC 2024 Downloads

2024-10-31 | Nomination Committee appointed in respect of AGM 2025 in Alligator Bioscience AB Downloads

2024-10-30 | Alligator Bioscience to Participate in Upcoming Scientific and Investor Conferences in Q4 2024 Downloads

2024-10-29 | Alligator Bioscience and Aptevo Therapeutics to Present Additional Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at SITC 2024 Downloads

2024-10-24 | Alligator Bioscience AB reports financial results for the first 9 months of 2024 and for Q3 2024 and provides a business update Downloads

2024-09-16 | Alligator Bioscience and Aptevo Therapeutics Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study Downloads

2024-09-13 | Alligator Bioscience and Aptevo Therapeutics to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types at ESMO Congress 2024 Downloads

2024-07-11 | Alligator Bioscience AB reports financial results for H1 2024 and Q2 2024 and provides a business update Downloads

2024-07-10 | Alligator Bioscience Announces Completion of Enrollment in Mitazalimab OPTIMIZE-1 Study Downloads

2024-06-26 | Alligator Bioscience Announces Substantial Overall Survival Benefit and Unprecedented Duration of Response in the 18-Month Analysis from Mitazalimab OPTIMIZE-1 Phase 2 Study in 1st Line Pancreatic Cancer Downloads

2024-06-25 | Alligator Bioscience announces financing of up to SEK 80 million extending cash runway to Q1 2025 Downloads

2024-06-20 | Alligator Bioscience to Present Positive Phase 2 Data on Mitazalimab in Pancreatic Cancer at ESMO GI 2024 Downloads

2024-06-14 | Alligator Bioscience Apppoints Johan Giléus as Chief Financial Officer Downloads

2024-06-03 | Alligator Bioscience’s Phase 2 mitazalimab Pancreatic Cancer Data Published in The Lancet Oncology Downloads

2024-05-23 | Alligator Bioscience to Present Positive Phase 2 Mitazalimab Data in Pancreatic Cancer at 2024 ASCO Annual Meeting Downloads

2024-05-21 | Alligator Bioscience’s Announces Henlius Biotech has Received FDA IND Clearance for Phase 3 Initiation to Evaluate HLX22 (AC101) in 1st Line HER2+ Advanced Gastric Cancer Downloads

2024-05-20 | Alligator Bioscience Announces Publication Highlighting Potential of Next-Generation CD40 Agonists in Peer-Reviewed Medical Journal “Expert Opinion on Biological Therapy” Downloads

2024-05-14 | Alligator Bioscience Announces Initiation of an Investigator-Initiated Initiation of Phase 1 Clinical Study of Intratumoral Mitazalimab in Locally Advanced Pancreatic Cancer Downloads

2024-05-07 | Bulletin from the annual general meeting in Alligator Bioscience AB on 7 May 2024 Downloads

2024-05-06 | Alligator Bioscience AB reports financial results for Q1 2024 and provides a business update Downloads

2024-04-30 | Change in number of shares and votes in Alligator Bioscience AB Downloads

2024-04-26 | Alligator Bioscience and Orion Corporation announce exercise of development option under 2021 Immuno-oncology Research Collaboration and License Agreement Downloads

2024-04-18 | Last day of trading in paid subscribed units (Sw. BTU) in Alligator Downloads

2024-04-09 | Alligator publishes outcome in rights issue Downloads

2024-04-08 | Alligator Bioscience Announces Two Presentations on Mitazalimab and ATOR-4066 at the AACR Annual Meeting 2024 Downloads

2024-04-05 | Notice of annual general meeting in Alligator Bioscience AB Downloads

2024-03-26 | Alligator Bioscience Announces Publication Highlighting its RUBY® Bispecific Antibody Format in the Scientific Journal “mAbs” Downloads

2024-03-22 | Alligator publishes supplementary prospectus Downloads

2024-03-21 | Alligator Bioscience publishes Annual Report for 2023 Downloads

2024-03-21 | The subscription period in Alligator Bioscience’s rights issue begins today Downloads

2024-03-15 | Alligator Bioscience publishes prospectus in connection with forthcoming rights issue Downloads

2024-03-14 | Bulletin from the extraordinary general meeting in Alligator Bioscience AB Downloads

2024-03-07 | Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4 Downloads

2024-02-08 | Notice of extraordinary general meeting in Alligator Bioscience AB Downloads

2024-02-08 | Alligator carries out a rights issue of units of approximately SEK 150.9 million with an over-allotment issue of up to an additional approximately SEK 100.0 million and raises bridge loans Downloads

2024-02-08 | Alligator Bioscience AB reports full year financial results for 2023 and for Q4 2023 and provides a business update Downloads

2024-02-08 | Alligator Bioscience Announces Cost Reduction Program to Align Key Priorities and Maximize Long-Term Value Creation Downloads

2024-01-29 | Alligator Bioscience Announces Positive Mitazalimab OPTIMIZE-1 Phase 2 Results Meeting Primary Endpoint and Demonstrating Clinically Relevant Survival Benefits in 1st Line Pancreatic Cancer Downloads

2024-01-16 | Alligator Bioscience Granted First U.S. Patent for Neo-X-Prime™ Bispecific Antibody ATOR-4066 for Cancer Treatment Downloads

2023-11-09 | Alligator Bioscience to Participate in Upcoming Industry Conferences in November 2023 Downloads

2023-11-06 | Correction: Nomination Committee appointed in respect of AGM 2024 in Alligator Bioscience AB Downloads

2023-11-06 | Nomination Committee appointed in respect of AGM 2024 in Alligator Bioscience AB Downloads

2023-11-03 | Alligator Bioscience Announces Poster Presentation on Neo-X-Prime Bispecific Antibody ATOR-4066 at SITC Annual Meeting 2023 Downloads

2023-10-31 | Alligator Bioscience Announces Capital Markets Day 2023 Downloads

2023-10-26 | Alligator Bioscience AB reports financial results for the first 9 months of 2023 and for Q3 2023 and provides a business update Downloads

2023-10-12 | Alligator Bioscience Granted New Composition of Matter Patent in Europe for Mitazalimab Downloads

2023-10-05 | Alligator Bioscience Announces Publication Highlighting ATOR-1017 Preclinical Data in the Scientific Journal “Cancer Immunology, Immunotherapy” Downloads

2023-10-03 | Alligator Bioscience to Participate in Upcoming Industry Conferences in October 2023 Downloads

2023-09-29 | Change in number of shares and votes in Alligator Bioscience AB Downloads

2023-09-28 | Alligator Bioscience Presents New Data Demonstrating Durable Response and Encouraging Anti-Tumor Activity of Lead Asset Mitazalimab Downloads

2023-09-27 | Alligator Bioscience Announces Publication Highlighting Pharmacodynamic Data from Mitazalimab Phase 1 Study in Scientific Journal “Cells” Downloads

2023-09-01 | Alligator receives approximately SEK 13.8 million through the exercise of warrants of series TO 6 Downloads

2023-08-21 | Alligator Bioscience Receives European Medicine Agency Orphan Designation for Mitazalimab in Pancreatic Cancer Downloads

2023-08-17 | The exercise period for Alligator’s warrants of series TO 6 begins today Downloads

2023-08-17 | Alligator Bioscience announces resignation of Malin Carlsson as Chief Operating Officer Downloads

2023-08-15 | Exercise price determined for the exercise of warrants of series TO 6 in Alligator Bioscience AB Downloads

2023-07-31 | Alligator Bioscience announce milestone achievement in 2021 Immuno-Oncology Research Collaboration and License Agreement with Orion Corporation Downloads

2023-07-13 | Alligator Bioscience AB reports financial results for H1 2023 and Q2 2023 and provides a business update Downloads

2023-07-11 | Alligator Bioscience to Present its CD40 Program at the 3rd Annual Tumor Myeloid-Directed Therapies Summit in July 2023 Downloads

2023-07-05 | Change in Employee Representatives to the Board of Directors of Alligator Bioscience AB Downloads

2023-06-30 | Change in number of shares and votes in Alligator Bioscience AB Downloads

2023-06-26 | Alligator Bioscience Announces Positive Second Interim Efficacy Analysis from Mitazalimab OPTIMIZE-1 Phase 2 Study in 1st Line Pancreatic Cancer Downloads

2023-06-13 | Alligator Bioscience to Host Virtual Key Opinion Leader Event on Mitazalimab Latest Interim Phase 2 Data in 1st Line Metastatic Pancreatic Cancer Downloads

2023-06-08 | Last day of trading in paid subscribed units (Sw. BTU) in Alligator Downloads

2023-06-05 | Alligator Bioscience to Present Latest Clinical Data from Mitazalimab OPTIMIZE-1 Phase 2 Trial in Pancreatic Cancer at ASCO Annual Meeting 2023 Downloads

2023-05-26 | Bulletin from the annual general meeting in Alligator Bioscience AB on 26 May 2023 Downloads

2023-05-24 | Alligator publishes supplementary prospectus Downloads

2023-05-18 | Alligator Bioscience Receives FDA Orphan Drug Designation for Mitazalimab in Pancreatic Cancer Downloads

2023-05-17 | Alligator announces final outcome of rights issue Downloads

2023-05-12 | Alligator announces preliminary outcome of rights issue Downloads

2023-05-12 | Alligator publishes supplementary prospectus Downloads

2023-05-11 | Alligator Bioscience and Orion Corporation announce exercise of development option under their 2021 Immuno-oncology Research Collaboration and License Agreement Downloads

2023-05-09 | Alligator publishes supplementary prospectus Downloads

2023-04-28 | The subscription period in Alligator Bioscience’s rights issue begins today Downloads

2023-04-27 | Alligator Bioscience & Amphera Announce Last Patient Treated in mitazalimab-MesoPher REACTIVE-2 Phase 1 Study in Pancreatic Cancer Downloads

2023-04-26 | Alligator Bioscience publishes prospectus in connection with forthcoming rights issue Downloads

2023-04-26 | Notice of annual general meeting in Alligator Bioscience AB Downloads

2023-04-25 | Alligator Bioscience AB reports financial results for Q1 2023 and provides a business update Downloads

2023-04-24 | Bulletin from the extraordinary general meeting in Alligator Bioscience AB Downloads

2023-04-18 | Alligator Bioscience Announces Poster Presentation on ATOR-4066 at the AACR Annual Meeting 2023 Downloads

2023-04-12 | Alligator Bioscience Announces Completion of Patient Enrolment in Mitazalimab OPTIMIZE-1 Phase 2 Trial in Pancreatic Cancer and Confirms Timeline for Top-Line Data in Q1 2024 Downloads

2023-04-03 | Alligator Bioscience Announces FDA Authorization to Initiate Mitazalimab OPTIMIZE-2 Phase 2 Trial in Urothelial Carcinoma Downloads

2023-03-24 | Alligator Bioscience publishes Annual Report for 2022 Downloads

2023-03-22 | Notice of extraordinary general meeting in Alligator Bioscience AB Downloads

2023-03-22 | Alligator intends to carry out a 91 percent secured rights issue of units of approximately SEK 199 million Downloads

2023-03-14 | Alligator Bioscience Announces KOL Interview on Mitazalimab and the Positive Interim Results from the OPTIMIZE-1 Phase 2 Trial in Pancreatic Cancer Downloads

2023-03-10 | Change in Employee Representatives to the Board of Directors of Alligator Bioscience AB Downloads

2023-02-14 | Change in Employee Representatives to the Board of Directors of Alligator Bioscience AB Downloads

2023-02-13 | Alligator Bioscience & Aptevo Therapeutics Announce Dosing of First Patient with ALG.APV-527 in Phase 1 Clinical Trial Downloads

2023-02-13 | Alligator Bioscience Announces the Promotion of Laura von Schantz to Chief Technology Officer Downloads

2023-02-10 | Alligator Bioscience AB reports full year financial results for 2022 and for Q4 2022 and provides a business update Downloads

2023-01-09 | Alligator Bioscience to Participate in Upcoming Scientific and Industry Conferences in January and February 2023 Downloads

2023-01-02 | Alligator Bioscience Announces Positive Interim Results from Mitazalimab OPTIMIZE-1 Phase 2 Trial in Pancreatic Cancer Exceeding 50% Objective Response Rate Downloads

2023-01-02 | Alligator Bioscience and Orion Corporation announce the initiation of the second program of their Immuno-oncology Research Collaboration and License Agreement Downloads

2022-12-22 | Alligator Bioscience Announces Publication Highlighting Phase 1 Mitazalimab Data in Solid Tumors in Peer-Reviewed Journal “Investigational New Drugs” Downloads

2022-12-13 | Alligator Bioscience to Participate in Upcoming Industry Events in January 2023 Downloads

2022-11-10 | Data presented on mitazalimab and ATOR-1017 in Two Poster Presentations at SITC Annual Meeting 2022 – November 8-12, 2022 Downloads

2022-11-09 | Alligator Bioscience & Aptevo Therapeutics Announce Publication Highlighting ALG.APV-527 Preclinical Data in Peer-Reviewed Journal Molecular Cancer Therapeutics Downloads

2022-11-08 | Alligator Bioscience Announces IND Approval for Second Phase 2 Clinical Trial of AC101 (HLX22) in Gastric Cancer developed by Shanghai Henlius Biotech in China Downloads

2022-11-02 | Alligator Bioscience Announces Publication Highlighting Bispecific Antibodies Targeting CD40 and Tumor Antigens in Peer-Reviewed Journal for ImmunoTherapy of Cancer Downloads

2022-11-01 | Alligator Bioscience to Participate in Upcoming Scientific and Industry Conferences Downloads

2022-10-24 | Nomination Committee appointed in respect of AGM 2023 in Alligator Bioscience AB Downloads

2022-10-20 | Alligator Bioscience AB reports financial results for the first 9 months of the year and for Q3 2022 and provides a business update Downloads

2022-10-17 | Invitation to the Presentation of Alligator Bioscience´s Interim Report January – September 2022 on October 20, 2022 Downloads

2022-10-10 | Alligator Bioscience to Present at 10th Annual Immuno-Oncology Summit, October 12 -14, 2022 Downloads

2022-09-30 | Alligator Bioscience Announces Positive Safety Data from 900 mg Dose Cohort in ATOR-1017 Phase 1 Dose Escalation Study in Patients with Advanced Solid Malignancies Downloads

2022-09-19 | Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a “May Proceed” Notification for the ALG.APV-527 IND Downloads

2022-09-14 | Alligator Bioscience Presents Additional Data from mitazalimab OPTIMIZE-1 Phase 1b/2 Trial at AACR Special Conference on Pancreatic Cancer 2022 Downloads

2022-09-06 | Alligator Bioscience to Participate in Upcoming Scientific Conferences in September 2022 Downloads

2022-07-12 | Alligator Bioscience AB reports H1 2022 and Q2 2022 financial results and provides a business update Downloads

2022-05-31 | Alligator Bioscience to Present Additional data of ATOR-1017 First-in-Human Study via poster presentation at ASCO Annual Meeting 2022 Downloads

2022-05-09 | Alligator Bioscience expands its Board of Directors with the appointment of Staffan Encrantz and Denise Goode Downloads

2022-05-05 | Bulletin from the annual general meeting in Alligator Bioscience AB on May 5, 2022 Downloads

2022-04-27 | Interim report January–March 2022 Downloads

2022-04-22 | Invitation to the Presentation of Alligator Bioscience´s Interim Report January – March 2022 on April 27, 2022 Downloads

2022-04-05 | Notice of annual general meeting in Alligator Bioscience AB Downloads

2022-04-01 | Alligator Bioscience Announces Completion of 600 mg Dose Cohort for ATOR-1017, Dose-escalation and Enrollment for 900 mg dose Cohort Commences Downloads

2022-03-31 | Change in number of shares and votes in Alligator Bioscience AB Downloads

2022-03-23 | Alligator Bioscience Announces mitazalimab OPTIMIZE-1 Trial Update: Successful Completion of Phase Ib, Phase II enrolling at 900 µg/kg Downloads

2022-03-22 | Issue and repurchase of series C shares for performance-based share saving program Downloads

2022-03-22 | Alligator Bioscience publishes Annual Report for 2021 Downloads

2022-03-11 | The Nomination Committee’s proposal regarding the Board of Directors ahead of the Annual General Meeting 2022 in Alligator Bioscience AB Downloads

2022-02-11 | Year End report January–December 2021 Downloads

2022-02-04 | Invitation to the Presentation of Alligator Bioscience´s Year-End Report January – December 2021 on February 11, 2022 Downloads

2022-02-01 | Alligator Bioscience Appoints Sumeet Ambarkhane MD as Chief Medical Officer Downloads

2022-01-20 | Nomination Committee Appointed in Respect of AGM 2022 in Alligator Bioscience AB Downloads

2022-01-19 | Alligator Bioscience Announces Commencement of a Sponsored Research Agreement with the University of Pennsylvania Led by Dr. Gregory Beatty Downloads

2022-01-18 | Alligator Bioscience Announces OPTIMIZE-1 Trial Update: Cohort Fully Dosed with No Adverse Effects Reported Downloads

2022-01-07 | Alligator Bioscience to Participate in Upcoming Investor Conferences Downloads

2021-12-30 | Change in number of shares and votes in Alligator Bioscience AB Downloads

2021-12-16 | Last day of trading in paid subscription shares (Sw. BTA) in Alligator Downloads

2021-12-16 | Alligator Bioscience Announces Trial Update and Early Readout for ATOR-1017 Confirming Biomarker, Safety & Tolerability Data Downloads

2021-12-15 | Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication in Peer-Reviewed Journal Nature Communication Downloads

2021-12-02 | Alligator carries out a directed issue of shares to guarantors in connection with the completed rights issue Downloads

2021-12-01 | Alligator announces final outcome of rights issue Downloads

2021-11-29 | Alligator announces preliminary outcome of rights issue Downloads

2021-11-12 | Alligator Announces Poster Presentation on ATOR-1017 at SITC Virtual Annual Meeting 2021 Downloads

2021-11-12 | Alligator Announces Poster Presentation on Neo-X-Prime™ presenting data on the lead compound targeting CD40 and CEA at SITC Virtual Annual Meeting 2021 Downloads

2021-11-12 | Alligator Announces Poster Presentation on OPTIMIZE-1 at SITC Virtual Annual Meeting 2021 Downloads

2021-11-12 | Alligator Bioscience and Aptevo Therapeutics Announce a Poster Presentation of ALG.APV-527 at SITC Annual Meeting 2021 Downloads

2021-11-12 | The subscription period in Alligator Bioscience’s rights issue begins today Downloads

2021-11-10 | Alligator Bioscience to Participate in Upcoming Investor Conferences Downloads

2021-11-08 | Alligator Bioscience Announces Commencement of Investigator Initiated Phase I Clinical Trial at Erasmus University Rotterdam Downloads

2021-11-08 | Bulletin from the extraordinary general meeting in Alligator Bioscience AB Downloads

2021-11-03 | Nomination Committee appointed in respect of AGM 2022 in Alligator Bioscience AB Downloads

2021-10-22 | Alligator enters into agreements on subscription commitments with board members and senior executives Downloads

2021-10-21 | Correction regarding MAR marking Downloads

2021-10-21 | Interim report January–September 2021 Downloads

2021-10-21 | Alligator Announces First Patient Dosed in Phase II Clinical Trial with Shanghai Henlius Biotech, Inc. & AbClon, Inc. Downloads

2021-10-15 | Invitation to the Presentation of Alligator Bioscience´s Interim Report January – September 2021 on October 21, 2021 Downloads

2021-10-07 | Notice of extraordinary general meeting in Alligator Bioscience AB Downloads

2021-10-07 | Alligator carries out a 100 percent secured rights issue of approximately SEK 257 million Downloads

2021-09-30 | Alligator Bioscience Announces First Patient Dosed in OPTIMIZE-1 Phase II Clinical Trial Evaluating Mitazalimab in Combination with mFOLFIRINOX for the Treatment of Pancreatic Cancer Downloads

2021-09-22 | Alligator to Participate in Upcoming Investor Conferences Downloads

2021-09-02 | Alligator is exploring financing alternatives to support phase II studies for Mitazalimab, phase II preparations for ATOR-1017 as well as the development of other pipeline Downloads

2021-09-02 | Positive Results from the Scandion Oncology and Alligator Bioscience Collaboration Further Supports Efficacy of Mitazalimab in Combination Therapy Downloads

2021-08-18 | Alligator Bioscience announces Immuno-oncology Research Collaboration and License Agreement with Orion Corporation Downloads

2021-08-16 | Alligator Bioscience Announces New Senior Director of Communications & Investor Relations Downloads

2021-07-13 | Interim report January–June 2021 Downloads

2021-06-30 | Alligator Bioscience AB and Scandion Oncology A/S present promising preclinical data Downloads

2021-06-07 | Article on CD40 agonistic antibodies published in Expert Opinion on Biological Therapy Downloads

2021-06-04 | Alligator Bioscience presents positive Phase I data at ASCO for its 4-1BB agonist drug candidate ATOR-1017 Downloads

2021-06-01 | Bulletin from the annual general meeting in Alligator Bioscience AB on June 1, 2021 Downloads

2021-05-05 | Alligator’s mitazalimab shown to enhance cancer vaccine Downloads

2021-05-04 | Alligator Bioscience and BioArctic enter into research agreement in the neurodegenerative field Downloads

2021-04-30 | Board member in Alligator Bioscience resigns at his own request Downloads

2021-04-27 | Interim report January–March 2021 Downloads

2021-04-26 | Notice of annual general meeting in Alligator Bioscience AB Downloads

2021-04-22 | The Nomination Committee’s proposal regarding the board of directors ahead of the annual general meeting 2021 in Alligator Bioscience AB Downloads

2021-04-15 | Alligator Bioscience and MacroGenics Enter into a Research Collaboration to Develop a Novel Immunotherapy Downloads

2021-04-03 | Alligator Bioscience postpones the Annual General Meeting to June 1, 2021 Downloads

2021-03-18 | Alligator Bioscience appoints Søren Bregenholt as new CEO Downloads

2021-03-18 | Alligator Bioscience publishes Annual Report for 2020 Downloads

2021-03-11 | Mitazalimab synergizes with chemotherapy – Alligator Bioscience presents new preclinical data at AACR Downloads

2021-02-26 | Change in number of shares and votes in Alligator Bioscience AB Downloads

2021-02-26 | Year-end Report January-December 2020 Downloads

2021-02-23 | Last day of trading in paid subscription shares (Sw. BTA) Downloads

2021-01-27 | Alligator Bioscience’s rights issue oversubscribed Downloads

2021-01-21 | Larger shareholder and board member transfer subscription rights free of charge to qualified investors Downloads

2021-01-15 | Alligator Bioscience appoints Chief Scientific Officer Downloads

2021-01-11 | The subscription period in Alligator Bioscience’s rights issue commences today Downloads

2020-12-30 | Alligator Bioscience publishes prospectus in connection with forthcoming rights issue Downloads

2020-12-29 | Alligator Bioscience recruits new Chief Medical Officer Downloads

2020-12-28 | Alligator Bioscience submits CTA for the mitazalimab Phase II study OPTIMIZE-1 Downloads

2020-12-15 | Alligator carries out a fully guaranteed rights issue of approximately SEK 86m Downloads

2020-12-10 | Alligator Bioscience launches ALLIGATOR-FAB™ – a novel human antibody library Downloads

2020-12-04 | Approved IND for Alligator Bioscience’s CD40-targeting antibody mitazalimab Downloads

2020-11-20 | Nomination Committee appointed in respect of AGM 2021 in Alligator Bioscience AB Downloads

2020-11-16 | Aptevo Therapeutics and Alligator Bioscience advancing the bispecific 4-1BBx5T4 antibody ALG.APV-527 into Phase I clinical development Downloads

2020-11-09 | Alligator Bioscience presents at the SITC 35th Annual Meeting Downloads

2020-11-05 | Alligator Bioscience presents the CD40 antibody mitazalimab at the World Immunotherapy Congress 2020 Downloads

2020-10-27 | Predicted therapeutic range dose levels reached in ATOR-1017 Phase I Downloads

2020-10-22 | Interim report January-September 2020 Downloads

2020-10-22 | Alligator Bioscience focuses on ATOR-1017 and mitazalimab Downloads

2020-09-28 | Alligator Bioscience appoints Gayle Mills as Chief Business Officer Downloads

2020-09-24 | Alligator Bioscience launches a new immuno-oncology concept Downloads

2020-09-16 | Alligator Bioscience receives patent approval for the drug candidate ATOR-1015 Downloads

2020-09-09 | Alligator Bioscience presents an update regarding the Phase I study with the drug candidate ATOR-1015 Downloads

2020-09-04 | Alligator Bioscience presents positive biomarker data demonstrating proof of mechanism in mitazalimab clinical Phase I study Downloads

2020-08-27 | Encouraging interim safety data in ATOR-1017 clinical Phase I study Downloads

2020-08-25 | Alligator Bioscience Virtual R&D Day – August 27, 2020 Downloads

2020-08-25 | Alligator Bioscience presents the clinical project portfolio at Virtual R&D Day August 27, 2020 Downloads

2020-07-13 | Alligator Bioscience AB (publ) Interim report January-June 2020 Downloads

2020-06-23 | Alligator Bioscience receives first patent approval for ATOR-1017 Downloads

2020-06-15 | Alligator Bioscience appoints new CFO Downloads

2020-06-10 | Aptevo Therapeutics and Alligator Bioscience present new preclinical data for ALG.APV-527 at the PEGS Virtual Interactive Global Summit Downloads

2020-06-04 | Alligator Bioscience and Scandion Oncology sign preclinical agreement to explore combination therapies for chemotherapy and immuno-oncology Downloads

2020-06-01 | Alligator Bioscience’s collaboration with Biotheus Inc. proceeds and second payment is received Downloads

2020-05-29 | Alligator Bioscience presents novel supportive Phase I data at ASCO for its CTLA-4 x OX40 bispecific drug candidate ATOR-1015 Downloads

2020-05-05 | Bulletin from the annual general meeting in Alligator Bioscience AB on May 5, 2020 Downloads

2020-04-27 | Alligator Bioscience presents promising interim Phase I data for its bispecific drug candidate ATOR-1015 at AACR Downloads

2020-04-23 | Alligator Bioscience AB (publ) Interim report January-March 2020 Downloads

2020-04-20 | Alligator Bioscience’s Board of Directors reduces its fees and offers possibility for postal voting in front of the Annual General Meeting Downloads

2020-04-07 | Alligator Bioscience increases focus on clinical development Downloads

2020-04-01 | Alligator Bioscience informs about temporary halt of recruitment of new patients due to the covid-19 pandemic Downloads

2020-03-31 | Notice of annual general meeting in Alligator Bioscience AB (publ) Downloads

2020-03-05 | Alligator Bioscience appoints Andreas Johannesson as interim Chief Financial Officer Downloads

2020-03-02 | Alligator Bioscience’s Annual Report 2019 published Downloads

2020-02-12 | Alligator Bioscience AB Year-end Report January-December 2019 Downloads

2019-12-17 | Alligator Bioscience: First patient dosed with ATOR-1017 developed for metastasized cancer Downloads

2019-12-11 | CFO Per-Olof Schrewelius leaves Alligator Bioscience Downloads

2019-11-29 | Alligator Bioscience AB appoints Chief Operating Officer Downloads

2019-11-13 | Nomination Committee appointed in respect of AGM 2020 in Alligator Bioscience AB Downloads

2019-11-08 | Aptevo Therapeutics and Alligator Bioscience present new preclinical data for ALG.APV-527 at the Society for Immunotherapy of Cancer 2019 Annual Meeting Downloads

2019-11-06 | Alligator Bioscience: ATOR-1017 Induces Long-Lasting Immunity – New Preclinical Data to be presented at SITC 34th Annual Meeting Downloads

2019-10-24 | Alligator Bioscience AB Interim report January-September 2019 Downloads

2019-08-20 | Alligator Bioscience signs antibody agreement for Greater China with Biotheus Inc. Downloads

2019-07-31 | Alligator Bioscience regains global rights from Janssen to CD40 agonistic antibody, ADC-1013 (JNJ-64457107) Downloads

2019-07-11 | Alligator Bioscience AB (publ) Interim report January-June 2019 Downloads

2019-06-18 | Alligator Bioscience submits clinical trial application for ATOR-1017 Downloads

2019-06-18 | Frontier – A Magazine about Alligator Bioscience and Immuno-oncology Downloads

2019-06-14 | Frontier – A Magazine about Alligator Bioscience and Immuno-oncology Downloads

2019-05-16 | Alligator Bioscience to present the ATOR-1015 Phase I study outline at ASCO Downloads

2019-05-15 | ADC-1013 clinical Phase I data to be presented at ASCO Downloads

2019-05-09 | Bulletin from the Annual Shareholders’ Meeting in Alligator Bioscience AB (publ) on May 9, 2019 Downloads

2019-04-17 | The Nomination Committee’s proposal for the annual shareholders’ meeting in Alligator Bioscience AB (publ) Downloads

2019-04-17 | Alligator Bioscience AB (publ) Interim report January-March 2019 Downloads

2019-04-11 | Preclinical data on the tumor-localizing anti-CTLA-4 antibody ATOR-1015 published in the Journal for ImmunoTherapy of Cancer Downloads

2019-04-10 | Notice of annual shareholders’ meeting in Alligator Bioscience AB (publ) Downloads

2019-04-10 | Alligator Bioscience to present new preclinical data on ATOR-1015 at PEGS Boston Downloads

2019-04-02 | New preclinical data for ATOR-1144 demonstrate potential for activation of both the innate and the adaptive immune system, as well as direct anti-tumor effects Downloads

2019-03-22 | Alligator Bioscience’s Annual Report 2018 published Downloads

2019-03-18 | New preclinical data demonstrate strong anti-tumor effects for the 4-1BB antibody ATOR-1017 Downloads

2019-03-07 | First Patient Dosed in Phase I study of ATOR-1015 Downloads

2019-02-14 | Alligator Bioscience AB Year-end Report 2018 Downloads

2019-02-12 | Alligator Bioscience to Host Conference Call to Provide Year-end Report 2018 Business Update Downloads

2019-01-29 | Alligator Bioscience publishes clinical phase I data for ADC-1013 in the International Journal of Cancer Downloads

2019-01-07 | Alligator Bioscience launches RUBY™, a novel concept in bispecific antibody formats Downloads

2018-12-11 | Alligator Bioscience starts clinical phase I study with ATOR-1015 Downloads

2018-12-10 | Frontier – A Magazine about Alligator Bioscience and Immuno-oncology Downloads

2018-11-09 | Alligator Bioscience and Aptevo Therapeutics Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting Downloads

2018-11-07 | Alligator Bioscience to receive million-dollar payments – AbClon partner exercises option Downloads

2018-11-06 | Nomination Committee appointed in respect of AGM 2019 in Alligator Bioscience AB Downloads

2018-10-30 | Alligator Bioscience expands pipeline: Preclinical development initiated for the candidate drug ATOR-1144 Downloads

2018-10-26 | Alligator Bioscience AB Interim Report January-September 2018 Downloads

2018-10-05 | Alligator Bioscience receives government research grant Downloads

2018-09-28 | New preclinical data support good tolerability properties for the 4-1BB antibody ATOR-1017 Downloads

2018-08-30 | Alligator Bioscience presents at the 20th Annual Rodman & Renshaw Global Investment Conference Downloads

2018-07-19 | Alligator Bioscience submits application to start clinical phase I study in cancer patients with ATOR-1015, a unique CTLA-4 and OX40 binding antibody Downloads

2018-07-12 | Alligator Bioscience AB Interim Report January-June 2018 Downloads

2018-06-25 | Frontier – A Magazine about Alligator Bioscience and Immuno-oncology Downloads

2018-06-21 | Alligator Bioscience’s ATOR-1017 strongly activates both T cells and NK cells, important for the effective eradication of tumor cells Downloads

2018-05-29 | Alligator Bioscience Capital Markets Day today on May, 29 Downloads

2018-05-16 | Invitation to Alligator Bioscience Capital Markets Day in Stockholm on May 29, 2018 Downloads

2018-05-08 | New Preclinical Data for Novel Immunotherapy Bispecific Candidate ALG.APV-527 presented by Alligator Bioscience and Aptevo Therapeutics Downloads

2018-05-03 | ATOR-1017 pre-clinical data support a best-in-class 4-1BB antibody profile Downloads

2018-04-26 | Bulletin from the Annual Shareholders’ Meeting in Alligator Bioscience AB (publ) on 26 April 2018 Downloads

2018-04-26 | Alligator Bioscience AB Interim Report January-March 2018 Downloads

2018-04-18 | Save the date: Alligator Bioscience to host Capital Markets Day in Stockholm on 29 May 2018 Downloads

2018-04-17 | Alligator Bioscience presents ATOR-1015 preclinical data at the AACR Annual Meeting 2018 confirming localized tumor activation Downloads

2018-04-05 | Alligator Bioscience presents at the H.C. Wainwright Annual Global Life Sciences Conference Downloads

2018-03-22 | Alligator Bioscience’s Annual Report 2017 published Downloads

2018-03-22 | Notice of annual shareholders’ meeting in Alligator Bioscience AB (publ) Downloads

2018-02-16 | Alligator Bioscience AB Full Year Report 2017 Downloads

2018-02-12 | Alligator Bioscience to Host Conference Call to Provide Full Year Report 2017 Business Update Downloads

2018-01-25 | Alligator Bioscience contracts Theradex Oncology as clinical CRO for the upcoming ATOR-1015 phase I study Downloads

2018-01-18 | Alligator Bioscience appoints new VP Business Development Downloads

2018-01-04 | Alligator Bioscience to Present at the 10th Annual Biotech Showcase Conference Downloads

2018-01-03 | Alligator Bioscience to receive USD 6 million milestone payment from Janssen coupled to the decision to initiate combination trial with ADC-1013 Downloads

2017-12-04 | Alligator Bioscience expands management team Downloads

2017-11-21 | Alligator Bioscience AB presents at Redeye Life Science Seminar 24 November 2017 Downloads

2017-11-13 | Nomination Committee appointed in respect of AGM 2018 in Alligator Bioscience AB Downloads

2017-11-07 | Results from Alligator Bioscience’s clinical phase I study support further clinical development of ADC-1013 Downloads

2017-10-25 | Alligator Bioscience AB Interim Report January-September 2017 Downloads

2017-10-24 | Alligator Bioscience Aptevo Therapeutics: Tumor antigen 5T4 associated with many forms of solid tumors identified as the second target for ALG.APV-527 Downloads

2017-09-21 | Alligator Bioscience to present ADC-1013 intratumoral clinical phase I study results at SITC in November 2017 Downloads

2017-09-13 | Alligator Bioscience signs immunotherapy research collaboration agreement for 4-1BB Downloads

2017-08-23 | Alligator Bioscience AB (Nasdaq Stockholm; ATORX) Interim report January – June 2017 Downloads

2017-08-17 | Aptevo Therapeutics and Alligator Bioscience commence IND-enabling development activities for new bispecific immunotherapy candidate ALG.APV-527 Downloads

2017-08-07 | Alligator expands immuno-oncology collaboration with Stanford University Downloads

2017-07-21 | Aptevo Therapeutics and Alligator Bioscience announce plans to co-develop novel bispecific antibody for tumor-directed immunotherapy Downloads

2017-06-12 | Alligator advances 4-1BB immuno-oncology antibody ATOR-1017 to pre-clinical development Downloads

2017-05-04 | Alligator Bioscience presents promising immuno-oncology data at US conference; – Strong new preclinical findings for ADC-1013 and ATOR-1015 Downloads

2017-05-02 | Bulletin from the annual shareholders’ meeting in Alligator Bioscience AB (publ) on May 2, 2017 Downloads

2017-05-02 | Alligator Bioscience AB Interim report January-March 2017 Downloads

2017-04-28 | Alligator Bioscience to present new pre-clinical data for ADC-1013 and ATOR-1015 at PEGS conference in Boston, May 4 Downloads

2017-03-31 | Change in number of shares and votes in Alligator Bioscience AB (publ) Downloads

2017-03-23 | Alligator announces completion of first phase I study with CD40 agonistic immuno-oncology antibody ADC-1013 Downloads

2017-03-22 | Alligator Bioscience Annual Report for 2016 published Downloads

2017-03-22 | Notice of annual shareholders’ meeting in Alligator Bioscience AB (publ) Downloads

2017-02-17 | Alligator Bioscience AB Full Year 2016 Report Downloads

2017-02-15 | Conference call for investors, analysts and the media on Friday, February 17 in connection with the company’s Full Year Report Downloads

2017-01-31 | Change in number of shares and votes in Alligator Bioscience AB (publ) Downloads

2016-12-30 | Change in number of shares and votes in Alligator Bioscience AB (publ) Downloads

2016-12-23 | Exercise of over-allotment option and notice of stabilisation in Alligator Bioscience Downloads

2016-12-16 | Notice of stabilisation measures Downloads

2016-12-09 | Notice of stabilisation measures Downloads

2016-11-30 | Change in number of shares and votes in Alligator Bioscience AB Downloads

2016-11-23 | Trading of Alligator Bioscience AB on Nasdaq Stockholm commences today Downloads

2016-11-14 | Alligator Bioscience AB publishes prospectus for Initial Public Offering on Nasdaq Stockholm Downloads

2016-11-02 | Nomination committee appointed in respect of AGM 2017 in Alligator Bioscience AB (Publ) Downloads

2016-11-02 | Alligator Bioscience AB intends to list its shares on Nasdaq Stockholm Downloads

2016-10-12 | Alligator Bioscience informs that dosing has started in a second clinical phase I study with the CD40 Agonistic Immuno-Oncology Antibody ADC-1013 Downloads